CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Sitagliptindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05725798
NCT05725798N/ACompleted
CompareCT.gov

Perioperative Sitagliptin Medication for Reduction of the Inflammatory Response Associated With Cardiopulmonary Bypass and Postoperative Glucose Control in Diabetic Patients Undergoing Elective Cardiac Surgery - a Pilot Study

University Hospital Muenster·observational·Posted Feb 13, 2023·Updated Aug 22, 2023

In Brief

An observational study evaluating Sitagliptin for Systemic Inflammatory Response Syndrome. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Sitagliptin is an inhibitor of the enzyme dipeptidylpeptidase-4 (DPP-4) and represents an established drug in type 2 diabetes mellitus treatment. However, Sitagliptin may also have several antiinflammatory properties. Within this study the investigators examine the effects of perioperative Sitagliptin intake on the inflammatory response after cardiopulmonary bypass.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Inflammatory Response Syndrome
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedFeb 13, 2023
Enrollment StartFeb 1, 2022
Primary CompletionMay 1, 2023
Study CompletionAug 1, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 3.4 years ago

Interventions

Sitagliptindrug

Group 1 who regularly takes Sitagliptin due to diabetes mellitus type 2 continues the treatment perioperatively. Group 2 and group 3 do not take Sitagliptin.